Researcher and clinician at RIKEN
Leader of the Retinal Regeneration Laboratory
What triggered the shutdown of your first human trial, launched in 2013?
In November 2014, a regulatory change required that any clinical study using stem cells be led by a medical institution. RIKEN being a research institute, our trial of age-related macular degeneration treatment had to be renewed. We then formed a new partnership with the Kobe General Hospital, Kyoto University and Osaka University to re-launch a clinical study.